why choose us

First received: March 29, 2023

Clinical Trial: Daratumumab in STK11 Mutated NSCLC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-small Cell Lung Cancer With STK11/LKB1 Mutation

Study Type: INTERVENTIONAL


Official Title: A Single-Arm Phase 2 Study of Daratumumab Subcutaneous (SC) in Previously Treated STK11/LKB1 Mutated Non-small Cell Lung Cancer

Brief Summary: This is a single-arm study of daratumumab in metastatic non-small cell lung cancer (NSCLC) patients with an STK11/LKB1 mutation.Patients will have received previous standard of care treatment including chemotherapy, immunotherapy and targeted therapy.Patients will be treated with the standard subcutaneous dosing of daratumumab (weekly for 8 administrations, then every 2 weeks for 8 administrations then every 4 weeks until progression).All follow-up visits and imaging will be performed as per standard of…

Read more